What is the clinical evidence from this study?

Study design: Other. Population: RBM20 mutant dilated cardiomyopathy (DCM). Intervention: All-trans retinoic acid. Primary outcome: Splicing of RBM20 target genes, calcium handling, and contractility.

What question did this study set out to answer?

The aim is to model RBM20-deficient dilated cardiomyopathy using iPSC technology and investigate therapeutic options.

September 1, 2020Cell ReportsOpen Access

iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy

View Full Paper

Ask AI

Bookmark

Key result

All-trans retinoic acid upregulated RBM20 expression and reverted splicing, calcium handling, and contractility defects in iPSC-CMs with causal RBM20 mutations.

Why the study?

Advances in iPSC technology make it possible to model genetic heart disease in vitro.

Does all-trans retinoic acid improve splicing, calcium handling, and contractility in iPSC-CMs with RBM20 mutations?

Population

iPSC-derived cardiomyocytes with three CRISPR/Cas9-introduced RBM20 mutations

Comparison

All-trans retinoic acid treatment

Design

In vitro preclinical study

Authors

FBFrancesca BrigantiAzienda Ospedaliera Sant'Andrea HSHan SunKunming Institute of Botany WWWei WuHuanggang Normal University

Discussion

Member takes

Implication

iPSC-CM models of RBM20 DCM enable mechanistic studies; leaves open clinical translation pending further validation.

Key Points

The aim is to model RBM20-deficient dilated cardiomyopathy using iPSC technology and investigate therapeutic options.
Utilized CRISPR/Cas9 to introduce RBM20 mutations into iPSCs and differentiated them into cardiomyocytes.
Evaluated splicing, calcium handling, and contractility in mutant iPSC-CMs.
Examined the effects of all-trans retinoic acid on RBM20 expression and cellular functions.
In RBM20 mutant iPSC-CMs, impaired splicing and contractility were observed.
All-trans retinoic acid upregulated RBM20 expression, improving calcium handling and contractility.
The Pro633Leu variant was confirmed as disease-causing, consistent with patient phenotypes.

Structured PICO

Does all-trans retinoic acid improve splicing, calcium handling, and contractility in iPSC-CMs with RBM20 mutations?

Population

induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with CRISPR/Cas9-introduced RBM20 mutations (including Pro633Leu) modeling dilated cardiomyopathy

Intervention

All-trans retinoic acid

Outcome

Splicing of RBM20 target genes, calcium handling, and contractilitysurrogate

Pharmacological upregulation of RBM20 expression with all-trans retinoic acid reverses disease phenotypes in an in vitro model of RBM20-deficient dilated cardiomyopathy.

Cite This Study

Briganti et al. (2020) studied RBM20 mutant dilated cardiomyopathy (DCM). All-trans retinoic acid was evaluated on Splicing of RBM20 target genes, calcium handling, and contractility. All-trans retinoic acid upregulated RBM20 expression and reverted splicing, calcium handling, and contractility defects in iPSC-CMs with causal RBM20 mutations.

synapsesocial.com/papers/6a56cef77d812fb23aa363ae https://doi.org/10.1016/j.celrep.2020.108117

View Full Paper

Ask AI

Bookmark

iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider